Quote this publication Share Print

BYETTA

-
Opinions on drugs - Posted on Nov 10 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.

-


Actual benefit

Important

The actual benefit of BYETTA is substantial.


Improvement in actual benefit

IV (mineur)

BYETTA provides a minor improvement in actual benefit (IAB IV) in the management of type-2 diabetes in patients treated with a combination of metformin and hypoglycaemic sulphonylurea who have not achieved adequate blood glucose control at the highest tolerated doses of these treatments.


Contact Us

Évaluation des médicaments
All our publication